Phase 2 Start

ACTU: Phase 2 Start: Phase 1/2 Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics,

Name: Phase 2 Start: Phase 1/2 Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics,
Start: 2026-10-01
End: 2026-10-01

October 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: October 1, 2026
Company: ACTUATE THERAPEUTICS, INC. (ACTU)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 2 Start~month

Phase 2 Start: Phase 1/2 Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics,

October 1, 2026

ACTU overview →

Company: ACTUATE THERAPEUTICS, INC. (ACTU)
Indication: Advanced Malignant Solid Tumor